Minodronic acid. Treatment of osteoporosis, treatment of bone metastasis, treatment of multiple myeloma

Drugs of the Future

Volumn 27, Issue 10, 2002, Pages 935-941

  Sorbera, L A ^a   Castaner J ^a   Leeson, P A ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; FLUORIDE; IBANDRONIC ACID; INCADRONIC ACID; MINODRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; BONE FRAGILITY; BONE MASS; BONE METASTASIS; BONE MINERALIZATION; BONE TISSUE; BONE TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEMALE; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC BONE DISEASE; MYELOMA; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0036820984     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.10.701186     Document Type: Review

References (34)

1. Casagrande, C., Invernizzi, A., Ferrari, G. Synthesis and pharmacological activity of imidazo-(1,2-a)-pyridine-2-acetic and 2,3-dicarboxylic acid and related compounds. Farmaco 1968, 23:1141-8.
2. Takeuchi, M., Sakamoto, S., Kawamuki, K., Kurihara, H., Nakahara, H., Isomura, Y. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives. Chem Pharm Bull 1998, 46: 1703-9.
3. Isomura, Y., Takeuchi, M., Abe, T. (Yamanouchi Pharmaceutical Co., Ltd.). Heterocyclic biphosphonic acid derivs. EP 0354806, US 4990503, US 5039669.
4. Takaoka, K., Ishii, M. (Yamanouchi Pharmaceutical Co., Ltd.). Novel preparation method of heterocyclic bis(phosphonic acid) derivs. JP 1999269184.
5. Prous Science Drug R&D Backgrounders: Osteoporosis (online publication). Updated October 17, 2002.
6. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA - J Am Med Assoc 2001, 285: 785-95.
7. Pfeilschifter, J., Diel, I.J. Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 2000, 18: 1570-93.
8. Altkorn, D., Vokes, T. Treatment of postmenopausal osteoporosis. JAMA - J Am Med Assoc 2001, 285: 1415-8.
9. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D.D., Golub, E., Rodan, G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88: 2095-105.
10. Rodan, G.A., Fleisch, H.A. Bisphosphonates: Mechanisms of action. J Clin Invest 1996, 97: 2692-6.
11. Shipman, C.M., Croucher, P.I., Russell, R.G., Helfrich, M.H., Rogers, M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58: 5294-7.
12. Derenne, S., Amiot, M., Barille, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.L., Bataille, R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999, 14: 2048-56.
13. Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H.P., Wilhelm, M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96: 384-92.
14. Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., Poulter, C.D., Ebetino, F.H., Rogers, M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296: 235-42.
15. Suzuki, K., Deyama, Y., Nishikata, M., Matsumoto, A. The effects of bisphosphonates on tyrosine phosphatase activity of osteoblastic cell line, MC3T3-E1. Jpn J Pharmacol 2001, 85(Suppl. I): Abst P-223.
16. Kurokouchi, K., Ito, T., Ohmori, S., Kanda, K., Murata, Y., Izumi, R., Inazu, M., Iwata, H., Seo, H. Effects of bisphosphonate on bone metabolism in tail-suspended rats. Environ Med 1996, 40: 39-42.
17. Kurokouchi, K., Ito, T., Ohmori, S., Kanda, K., Murata, Y., Yasukawa, K., Izumi, R., Inazu, M., Iwata, H., Seo, H. Administration of bisphosphonate prevents disuse bone atrophy induced by tail suspension. Environ Med 1997, 41: 16-7.
18. Ohmori, S., Kurokouchi, K., Kanda, K., Kawano, S., Ito, T., Inazu, M., Kambe, F., Seo, H. Changes in urinary excretion of deoxypyridinoline in tail-suspended rats: Effects of a bisphosphonate, YH529. Environ Med 1998, 42: 11-3.
19. Ohmori, S., Kurokouchi, K., Kanda, K., Kawano, S., Ito, T., Izumi, R., Yasukawa, K., Inazu, M., Murata, Y., Seo, H. Effect of bisphosphonate administration on the excretion of stress hormones in tail-suspended rats. Environ Med 1997, 41: 9-12.
20. Mori, H., Tanaka, M., Ochi, Y., Kawada, N., Yamada, H., Matsuda, T., Kawabata, K., Obata, T. Effects of long-term treatment with minodronate on bone loss and mechanical strength in ovariectomized rats. Osteoporosis Int 2002, 13(Suppl. 1): Abst P111SU.
21. Yoshida, Y., Moriya, A., Kitamura, K., Inazu, M., Okimoto, N., Okazaki, Y., Nakamura, T. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 1998, 13: 1011-22.
22. Yamane, I., Yamasaki, D., Enokida, M., Okano, T., Hagino, H., Teshima, R. Effect of minodronate (Ono-5920) in adult rats with collagen-induced arthritis. J Bone Miner Res 2002, 17(Suppl. 1): Abst SU347.
23. Shibasaki, K., Tanaka, S., Katou, N., Yuyama, H., Koutoku, H., Miyata, K. Inhibition of tumor-induced osteolysis by minodronic acid (YM529) in nude mice with bone metastases. J Bone Miner Res 2002, 17(Suppl 1): Abst SA245.
24. Sasaki, A., Kitamura, K., Alcalde, R.E., Tanaka, T., Suzuki, A., Etoh, Y., Matsumura, T. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998, 77: 279-85.
25. Funatsu-Ozawa, Y., Hiraga, T., Tanaka, S., Asano, H., Kageyama, K., Motoie, H., Ozawa, H. Oral administration of bisphosphonate YM529 inhibits tumor-induced osteolysis in rodents with bone metastases. J Bone Miner Res 1997, 12(Suppl 1): Abst F683.
26. Takahashi, R., Shimazaki, C., Inaba, T., Okano, A., Hatsuse, M., Okamoto, A., Hirai, H., Ashihara, E., Nakagawa, M. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001, 25: 77-83.
27. Yata, K., Otsuki, T., Yamada, O., Wada, H., Yawata, Y., Sugihara, T. Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells. Int J Hematol 2002, 75: 534-9.
28. Usui, T., Kawakami, R., Watanabe, T., Higuchi, S. Sensitive determination of a novel bisphosphonate, YM529, in plasma, urine and bone by high-performance liquid chromatography with fluorescence detection. J Chromatogr - Biomed Appl 1994, 652: 67-72.
29. Nakamura, K., Tanaka, T., Saito, K., Yokohama, S., Sonobe, T. Stabilization of minodronic acid in aqueous solution for parenteral formulation. Int J Pharm 2001, 222: 91-9.
30. Nakamura, K., Yokohama, S., Sonobe, T. Failure of stability prediction for minodronic acid injectable by accelerated stability testing. Int J Pharm 2002, 241: 65-71.
31. Morii, H., Minaguchi, H., Inoue, T., Yamamoto, K., Nawata, S., Kushida, K., Fukunaga, Y., Miki, T., Ohashi, Y. Effect of minodronate on bone parameters and bone mineral density in post-menopausal osteopenia. J Bone Miner Res 1997, 12(Suppl. 1): Abst S483.
32. Morii, H., Nishizawa, Y., Taketani, Y. et al. A randomized controlled trial with Ono-5920 (minodronate/YM529) in Japanese patients with postmenopausal osteoporosis. J Bone Miner Res 2002, 17(Suppl. 1): Abst M342.
33. Research and development pipeline. Yamanouchi Web Site May 2002.
34. Annual Flash Report. Ono Pharmaceutical Web Site May 17, 2002.